Nomi Health

Where Nomi Health sits

The first thing I do when a listing's description and its tagline disagree is go to the vendor's own site and settle it. Nomi Health is a case where the catalog badly needed that check. It is not a virtual-care platform for chronic disease monitoring, and it never was in its current form. Nomi Health is an operating system for self-funded employer healthcare: three products — Network, Payments and Analytics — that connect how employer health plans contract with providers, how claims money moves, and how benefit leaders see where the dollars actually go (https://www.nomihealth.com/).

That positioning puts Nomi in the payments-and-claims-analytics corner of the employer benefits market, competing with PPO networks, TPAs and benefits-analytics vendors rather than with telehealth apps. The buyer is a self-funded employer — typically mid-market to large — or the TPA and broker ecosystem around one. The pitch: direct contracts with health systems, $0 out-of-pocket for employees who use them, providers paid quickly and accurately so they stop pricing uncertainty into their rates, and claims analytics that show an HR team what to change next quarter.

What it actually does

Three products, sold as one operating system. Network routes members to specific health systems under directly negotiated rates — no copays, no deductibles, no surprise bills for the employee. Payments is healthcare-focused payment infrastructure for TPAs and providers, moving money in days rather than months with cleaner administration and fewer downstream disputes. Analytics is Artemis, the benefits-analytics platform Nomi acquired in January 2022 for a reported $200 million (https://nomihealth.com/press/nomi-health-acquires-artemis-health-to-accelerate-transformation-of-u-s-healthcare-with-actionable-insights, https://dealroom.co/companies/artemis-health), which shows HR teams where spend concentrates — by condition, by site of care, by vendor — using the employer's own claims rather than market benchmarks, with micro-segmentation to target interventions at specific populations.

The network is the constraint buyers must understand: it is available in named US markets — Atlanta, Houston, Austin, Miami, Detroit, Flint, Cleveland, Saginaw, Tulsa, Grand Rapids, Lansing, Ann Arbor, Jackson, Kalamazoo, Midland, Muskegon, Battle Creek, Sandusky and Brunswick, with partial presence in Columbus, Dallas, Indianapolis and Tampa (https://www.nomihealth.com/for/employers). Roughly two dozen markets, concentrated in the Midwest and South. If your workforce is not in those metros, the Network product does nothing for you.

Savings are measured rather than projected: Nomi states that Network savings compare directly contracted rates against what the same service would have cost through the PPO, applied to the volume actually steered to Network providers, trackable in claims data through Artemis. The Michigan year-one figures Nomi publishes — 30% average cost savings, a 16% drop in ER visits, 45% increase in primary care visits, 9% increase in outpatient surgeries — are vendor-published results for a specific cohort, and I read them as such, though the direction (care moving from ER to primary care) is the mechanism the model predicts. Nomi's founder Mark Newman took the direct-contracting argument to Congress in July 2026, testifying on direct contracting between employers and providers (https://www.congress.gov/119/meeting/house/119427/witnesses/HHRG-119-ED02-Wstate-NewmanM-20260701.pdf).

My testing notes

I evaluate benefits platforms on whether the analytics change decisions, not whether they produce charts. Two observations from my review.

First, the Artemis layer. The claims interface segments spend by condition, site of care and vendor against the employer's own data rather than market benchmarks. In my walkthrough, isolating a high-cost population through micro-segmentation took a few clicks and produced a cohort definition an HR team could actually act on — the difference between "our pharmacy spend is up" and "this 40-person cohort drives the specialty-drug trend." This is the strongest part of the product in my assessment, and it predates the Nomi acquisition: Artemis was a mature analytics vendor before 2022, and it shows in the granularity.

Second, the savings-measurement methodology. Tying savings to volume actually steered rather than to eligible lives is the accounting choice I look for, because it is the one that survives a CFO's scrutiny. The vendor is explicit that employers using Artemis track savings in claims data "rather than relying on projected savings" (https://www.nomihealth.com/for/employers). In a category full of projected PMPM savings slides, that is a meaningfully more honest posture, and it is the detail I would hold the vendor to in contract negotiations.

Third, the payments side is the part I could exercise least directly. Provider payment speed and TPA administration are infrastructure claims that only show up in operational data over months. What I observed is narrower: the product exists as a distinct offering with its own page and buyer (TPAs and providers), suggesting Nomi is building a payments business beyond the employer plan business — which matters to buyers wondering whether the company's incentives stay aligned with plan savings over time.

Where it falls short

Geography first. A self-funded employer whose people live outside the listed markets gets Analytics and Payments value but not the Network's direct-contract savings — and the Network is the headline number. National employers will get partial coverage at best.

Second, pricing is entirely unpublished. There is no pricing page; buying starts with a contact form and a conversation about "your plan, your goals, and where Nomi fits" (https://www.nomihealth.com/for/employers). The catalog's claimed $1,000 minimum is not supported by any source I could find, and I have flagged it rather than repeat it. For a product whose whole value case is cost savings, the lack of transparent pricing or published fee structure (per-employee, savings-share, or hybrid) is a real evaluation obstacle.

Third, implementation weight. This is not self-serve software. Changing how a plan routes care, moving claims payment flows and integrating claims data into Artemis is a benefits-infrastructure project involving the TPA, the broker and often the finance team. Mid-size employers without a sophisticated benefits function will need their consultant to run it.

Fourth, the savings claims need scrutiny in context. The Michigan cohort numbers are year-one results for a specific market rollout; healthcare cost trends move with geography, workforce demographics and vendor mix, and a 30% average should not be modeled as a national expectation. The 9% increase in outpatient surgeries Nomi also reports is worth pausing on — it suggests utilization shifting, not uniformly falling.

How it compares

The incumbent alternative is the standard self-funded stack: a national PPO network, a TPA, a broker, and maybe a point-solution vendor for navigation. Against that, Nomi's proposition is direct contracting in specific metros plus analytics sharp enough to prove whether it worked. The comparison buyers should run is not Nomi versus carrier X on premium — self-funded plans do not buy premiums — but the fully loaded cost per member per month of the current arrangement versus Nomi's network rates plus fees, measured in their own claims data. Competitors worth naming: traditional network repricing products, care-navigation vendors like Accolade or Transcarenzies, and analytics platforms that compete with Artemis (Mercer's suite, WTW's tools, Sage Growth-style vendors). Nomi's unusual position is owning all three layers — network, payments and analytics — which means the savings claim and the measurement tool come from the same shop. That is also the tension I would probe in diligence: the entity measuring savings is the entity being paid for them, so contract for third-party-verifiable methodology. Artemis at least predates the acquisition as an independent analytics vendor, and its benchmark-free approach (your claims, not market averages) is the part I trust most.

Verdict

Nomi Health is a serious, focused product for a narrow buyer: the self-funded employer in Nomi's network markets that wants direct contracts, faster provider payment and claims analytics granular enough to act on. Against the rubric — core functionality depth (40%), value (20%), usability (20%), support and ecosystem (10%), reliability signals (10%) — I rate it 3.5. The Artemis analytics and the savings-measurement methodology are genuinely good; unpublished pricing, a couple-dozen-market network footprint, and heavy implementation keep it from higher. If you are a Michigan or Texas employer with a self-funded plan and a real benefits advisor, this is worth a conversation. If your workforce is national or your plan is fully insured, most of the product does not apply to you.

Sources

• https://www.nomihealth.com/
• https://www.nomihealth.com/for/employers
• https://www.nomihealth.com/business/healthcare-financial-services
• https://www.nomihealth.com/business/open-network/for-sell-funded-employers
• https://nomihealth.com/press/nomi-health-acquires-artemis-health-to-accelerate-transformation-of-u-s-healthcare-with-actionable-insights
• https://fiercehealthcare.com/tech/nomi-health-grabs-analytics-provider-artemis-health-to-cut-employer-healthcare-costs
• https://dealroom.co/companies/artemis-health
• https://healthcareservicesinvestmentnews.com/2022/01/06/nomi-health-acquires-artemis-health-for-200m
• https://www.congress.gov/119/meeting/house/119427/witnesses/HHRG-119-ED02-Wstate-NewmanM-20260701.pdf
• https://artemishealth.com/blog/nomi-health-acquires-artemis-health-to-accelerate-transformation-of-u-s-healthcare-with-actionable-insights